Enable JavaScript to visit this website.
Skip directly to content

Monoferric (iron isomaltoside 1000 for injection) Now Available in Canada


Kirkland, QC, October 22, 2018 - Pfizer Canada and Pharmacosmos A/S are pleased to announce that MonoferricTM which is indicated for the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy is now approved and available in Canada. Pfizer Canada has the exclusive commercialisation rights to MonoferricTM in Canada.

“Patients with iron deficiency anemia can have symptoms that significantly affect the quality of their life on a daily basis,” says Dr. Wendy Lim, Professor in the Department of Medicine, Division of Hematology and Thromboembolism at McMaster University, Hamilton, Canada. “Having another option for delivering iron replacement allows us to effectively treat these patients and allow them to have more productive lives.”   

“Pfizer is pleased to be able to make MonoferricTM available in Canada,” says Cole Pinnow, head of Pfizer’s Essential Health business unit in Canada.  “We believe strongly that this new treatment option reinforces Pfizer’s ongoing commitment to bringing innovative solutions to the lives of Canadian patients.”

About MonoferricTM

MonoferricTM (iron isomaltoside 1000 for injection) is an iron-carbohydrate complex for intravenous administration. MonoferricTM is marketed in more than 30 countries worldwide for the treatment of iron deficiency and iron deficiency anaemia. MonoferricTM is under development in the USA and Japan. MonoferricTM is manufactured by Pharmacosmos A/S, Denmark.

About iron deficiency anaemia (IDA)

Iron deficiency anaemia (IDA) is a debilitating condition that affects almost 2 billion people worldwide. IDA is often associated with many chronic disorders such as renal diseases (including Chronic Kidney Disease), cancers (including chemotherapy-induced anaemia), gynaecologic disorders (including abnormal uterine bleeding) and inflammatory bowel disease (IBD).

About Pharmacosmos A/S

Pharmacosmos A/S is a family-owned Danish pharmaceutical company headquartered in Holbæk, Denmark. The company was founded in 1965 and today sells its products in the UK, Scandinavia and Germany through its own subsidiaries and across the world through partners. Pharmacosmos is a global leader in the development and marketing of medicines for the treatment of iron deficiency and iron deficiency anaemia. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with an unrivalled expertise in the synthesis of iron-carbohydrate complexes to bring better treatments for patients suffering from iron deficiency. The state-of-the-art facilities in Denmark are approved by both the Danish Medicines Agency and the US Food & Drug Administration.

About Pfizer Canada

Pfizer Canada is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines, vaccines and consumer health products. Every day, Pfizer Canada employees work to bring therapies to patients that significantly improve patients’ lives. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything we do, from our disease awareness initiatives to our community partnerships. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/Pfizer.Canada).

For more information about MONOFERRIC:

Pfizer Canada Medical Information @ 1-800-463-6001; www.pfizermedicalinformation.ca


For media/external inquiries

Pfizer Canada Corporate Affairs
[email protected]